Femtomolar molecular insight across RNA, DNA and protein biomarkers—all from one pocket-sized reader. Anywhere. Anytime.
Sensitivity vs. ELISA/qPCR
Result delivery
Sample volume
Reported accuracy
Two reported patents securing the core detector and nano-biosensor architecture.
Backed by 12 PhD researchers and a massive 15-year institutional R&D foundation.
ICMR-CCMB validation including a rigorously reported 94.2% clinical accuracy.
A single reader unit designed to support infinite new panels purely through cartridge changes.

Genomics & AI
Karolinska Institute / Oxford-trained specialist leading global partnerships.

Nano-biosensors
IIT Hyderabad pioneer leading core R&D, IP and manufacturing scale-up.

Scale & Partnerships
Vodafone / Reliance veteran executing commercial strategy and rollout.

Institutional Partner
Embedded researchers, platform patents and deep scientific foundations.
Keep the detector. Change the “fishing hook” cartridge to target a new biomarker—without re-engineering the reader architecture.
Trop-X · NTProBNP
RNA · DNA panels
18+ biomarkers profiling
Pathogen · water panels
Swap the cartridge to serve new needs across healthcare, diagnostics, beauty and future self-care sectors globally.
Cardiac and respiratory panels deployed from emergency departments to community scale screening initiatives.
Molecular skin profiling with 18+ biomarkers driving highly personalized, science-backed consumer experiences.
License our nano-core architecture to upgrade existing systems with molecular sensitivity.
A future direct-to-consumer platform with high-margin recurring cartridge potential after partner-led scale.
Choose a pilot, a platform license or a white-label program.
Deploy X-Home™ at scale. Use multiplex cardiac panels in emergency, cardiology and pathology settings.
Build screening programs. Explore cardiac screening, infectious-disease surveillance and rural health.
License the platform. Integrate with existing point-of-care readers and jointly validate new biomarkers.
Offer molecular profiling. Develop white-label testing around 18+ skin biomarkers.
Foundational research at IIT Hyderabad and selective biomarker capture protocols.
Femtomolar sensitivity proof of concept and multiple biomarkers on one platform.
Detector architecture IP filed. Reported 94.2% accuracy in COVID RNA and Cardiac panels.
Handheld reader finalized, robotic GMP process secured. Prepared for pilots and licensing.
| Approach | Molecular readout | Format & sample | Panel flexibility |
|---|---|---|---|
| BioKubit X-Home™ | RNA, DNA & protein | Handheld · <5 µL · <30 mins | Multiplex · swappable cartridge |
| Surface imaging | Visual surface signals | Imaging equipment | Visual features |
| Lab genomics / ELISA | Molecular | Laboratory workflow | Defined assays |
Funding hospital pilots, government POC deployments, and device licensing partnerships. With a clear structural path to a massive $1B+ exit projection.
Discuss the opportunity
Outline a hospital deployment, government POC, licensing, beauty partnership or investor conversation.
IIT Hyderabad incubated · ICMR-CCMB validated · TRL 7–8